RareStone Group

Rare Stone Group

Pharmaceuticals, 5785 BLVD, Indianapolis, Indiana, Washington, 46220, United States, 51-200 Employees

rarestonegroup.com

  • twitter
  • LinkedIn

Who is RARESTONE GROUP

RareStone Group is dedicated to building the first rare disease ecosystem in the Greater China, to improve the lives of patients and families impacted by rare diseases, by bringing the be...

Read More

map
  • 5785 Washington BLVD, Indianapolis, Indiana, 46220, United States Headquarters: 5785 Washington BLVD, Indianapolis, Indiana, 46220, United States
  • 2019 Date Founded: 2019
  • 51-200 Employees: 51-200
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

checked-icon Does something look wrong? Fix it. | View contact records from RARESTONE GROUP

RareStone Group Org Chart and Mapping

Employees

Casey Slattery

Manager of Business Development and Licensing

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding RareStone Group

Answer: RareStone Group's headquarters are located at 5785 BLVD, Indianapolis, Indiana, Washington, 46220, United States

Answer: RareStone Group's official website is https://rarestonegroup.com

Answer: RareStone Group's revenue is $1 Million to $5 Million

Answer: RareStone Group has 51-200 employees

Answer: RareStone Group is in Pharmaceuticals

Answer: RareStone Group contact info: Phone number: Website: https://rarestonegroup.com

Answer: RareStone Group is dedicated to building the first rare disease ecosystem in the Greater China, to improve the lives of patients and families impacted by rare diseases, by bringing the best-in-the-world therapeutic solutions and comprehensive and sustainable service supports. RareStone Group consists of two business subsidiaries: Citrine Medicine and Zircon Health. Citrine Medicine is a pharmaceutical company and focused on providing effective and affordable therapeutic solutions to rare disease patients in the Greater China. Citrine Medicine currently focuses on 4 therapeutic areas: neurology, endocrinology, liver, kidney & metabolic diseases, and rare oncology. Citrine already has two assets WAKIX & Alkindi in pre-NDA stage for rare diseases in neurology and endocrinology, respectively. Zircon Health is a service company and aims to build the first ecosystem for rare disease in China, providing a patient-centered service platform for full disease management by leveraging AI, internet tools and big data analytics, and developing solutions to meet the unmet non-treatment needs of rare disease patients and families, as well as exploring innovative payment solutions to improve affordability. RareStone Group closed a USD80 million Series A financing in July 2020. Key investors include Eight Roads Ventures, F-Prime Capital, Vivo Capital. Our Vision: To become the leading company supporting the rare disease community in China. Our Mission: To provide individuals and families in China affected by rare diseases with access to the best, most effective medicines and treatment protocols available in the world. Our Approach: To build the first rare disease ecosystem in China to bring a support network and much needed treatments to individuals and their families affected by rare diseases.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access